$9.67
-0.96-9.03%
Last update: Nov 5, 4:00 PM
Design Therapeutics Inc (DSGN) Stock Price, Quote, News & History
DSGNNASDAQ
Design Therapeutics reported Phase 1/2 data for DT-216P2, showing biomarker and clinical improvements in Friedreich ataxia patients.
You can purchase shares of Design Therapeutics (NASDAQ:DSGN) through any online brokerage.
Other companies in Design Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Design Therapeutics has a consensus price target of $16.25.
The stock price for Design Therapeutics (NASDAQ: DSGN) is $9.67 last updated November 5, 2026 at 4:00 PM EST.
There are no upcoming dividends for Design Therapeutics.
Design Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Design Therapeutics.
Design Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be...
